Hepatitis

The global hepatitis C virus epidemic faces several barriers and meeting WHO target goals will be difficult unless a vast strategy is implemented.

Scaling up prevention, treatment, and screening interventions can make substantial strides toward global hepatitis C elimination.

Post-cure care for hepatitis C can reduce the risk of liver disease progression in those with advanced fibrosis and ongoing risk factors for liver injury.

Universal hepatitis screening may be warranted to identify patients with cancer who have undiagnosed viral infections.

Top news of the day across the health care landscape

Clear differences in hepatitis C virus worldwide indicate the need to increase global understanding of the virus.

Understanding the rate of hepatitis C infection is critical for making strategies to reduce the disease burden among specific populations.

Application of core area methodology can help identify new hepatitis C cases and outbreaks and improve testing and treatment.

People who inject drugs may not accurately self-report HIV and antiretroviral drug status when entering an HIV prevention study.

Patients with hepatitis C virus treated with direct acting antiviral drugs showed successful long-term outcomes regardless of receiving opioid substitution therapy for drug addiction.

Combination of glecaprevir and pibrentasvir for hepatitis C virus genotype 3 effective over an 8-week treatment duration.

Community-acquired pneumonia is a major cause of mortality and morbidity among patients with HIV.

A substantial portion of mortality from liver cirrhosis and hepatocellular carcinoma can be attributed to the extrahepatic manifestations associated with hepatitis C virus.

Making the patients’ lives easier is at the heart of my job.

Study finds that treating hepatitis C reduced the risk of developing the signs and symptoms of Parkinson disease.

Researches seeking to eliminate HIV are close enough to see the finish line, but with no idea how far away they are from a cure.

Here are the top articles from our hepatitis coverage of the year.

Top news of the day across the health care landscape.

Foreign-born black women aren’t benefiting from HIV prevention programs at the same rates as other women.

Study highlights the importance of testing and early intervention in young patients with hepatitis C virus.

A recent study found further evidence that hepatitis C reinfection rates are greater in drug users despite successful treatment with direct-acting antiviral therapy.

Emerging platforms make it feasible for hepatitis C testing to be conducted in settings that within or outside of health care facilities, such as prisons.

Study shows that routinely screening inmates for hepatitis C virus at entry may identify a significant number of cases that would have been missed through targeted testing.

Bodily fluids may serve as vectors for transmission for transmitting hepatitis C virus RNA in patients with a high viral load.

HIV is not associated with preterm delivery, though antiretroviral therapy is, but hepatitis C may be a potential risk factor.

Detecting hepatitis C RNA in peripheral blood mononuclear cells or liver cells in patients who are negative for viral RNA raises questions about the risk of transmission to other individuals.

Early detection is vital to more patients with hepatitis C virus being eligible for increasingly efficient direct-acting antiviral treatment options.

Tailoring hepatitis C treatments to shorten regimen length can reduce costs and ease burden for patients with limited insurance benefits.

Direct-acting antivirals are a costly but highly-effective class of drugs for the treatment of hepatitis C that can cure most cases.

One hundred percent of patients with hepatitis C virus genotypes 1, 2, 4, 5 and 6 achieved a sustained virologic response at 12 weeks post treatment with 8 weeks of glecaprevir/pibrentasvir treatment.